Seasoned operator-turned-investor active in growth-stage technology and software markets, Nicholas McElroy brings operating, fundraising and board-level experience to venture and private equity engagements. Focuses on scaling SaaS, fintech and digital marketplace businesses, advising management teams on go-to-market, product-market fit and capital strategy. Known for hands-on portfolio involvement, capital allocation discipline and bridging founders to institutional LPs and strategic acquirers.
Seasoned operator-turned-investor active in growth-stage technology and software markets, Nicholas McElroy brings operating, fundraising and board-level experience to venture and private equity engagements. Focuses on scaling SaaS, fintech and digital marketplace businesses, advising management teams on go-to-market, product-market fit and capital strategy. Known for hands-on portfolio involvement, capital allocation discipline and bridging founders to institutional LPs and strategic acquirers.
Operator-led growth investor who prioritizes scalable SaaS, fintech and digital marketplace opportunities, deploying capital at Series A–C with a bias toward value creation over short-term exits. Applies hands-on operating playbooks to accelerate go-to-market, product–market fit and unit economics while preserving disciplined portfolio construction and capital allocation. Seeks founder-aligned governance, measurable KPIs, and strategic paths to institutional follow-on funding or acquisition, leveraging board experience and LP/acquirer networks.
Operator-led growth investor who prioritizes scalable SaaS, fintech and digital marketplace opportunities, deploying capital at Series A–C with a bias toward value creation over short-term exits. Applies hands-on operating playbooks to accelerate go-to-market, product–market fit and unit economics while preserving disciplined portfolio construction and capital allocation. Seeks founder-aligned governance, measurable KPIs, and strategic paths to institutional follow-on funding or acquisition, leveraging board experience and LP/acquirer networks.
| Trades 1462 | Longs Won 1008/1462 68% | Profit Factor 7.06 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.78M |
| Average Win $296,668.95 | Best Trade (Jun 30) $50.93M | Sharpe Ratio -3.31 |
| Average Loss -$93,301.09 | Worst Trade (Sep 30) -$3.66M | Z-Score 6.69 (100%) |
| Commissions $0 | Avg. Trade Length 1y 1m 4w 1d | Expectancy $175,570.18 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 10,204 | 9,184 | 8,163 | 7,143 | 6,122 | 5,102 | 4,082 | 3,061 | 2,041 | 1,020 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 7840 78409V112 | 736 | $299,878 | $299,878 | - | - | - | 0.0 |
AAPL Apple Inc. | 19,082 | $4.28M | $6.58M | - | $2.31M | 53.91% | +0.901% |
ABT Abbott Laboratories | 281,731 | $25.66M | $29.54M | - | $3.87M | 15.09% | +0.148% |
ACWX ISHARES MSCI ACWI EX U.S. ETF | 37,648 | $2.02M | $2.82M | - | $795,825.1 | 39.35% | +0.295% |
AGG iShares Core U.S. Aggregate Bond ETF | 3,603 | $349,130.32 | $344,176.57 | - | -$4,953.75 | -1.42% | +0.121% |
ALLY Ally Financial Inc. | 109,742 | $3.91M | $4.19M | - | $282,589.14 | 7.24% | +1.153% |
AMGN Amgen Inc. | 8,948 | $2.88M | $3.9M | - | $1.02M | 35.39% | +0.514% |
AMZN Amazon.com Inc | 6,856 | $1.15M | $1.74M | - | $590,081.37 | 51.39% | -0.471% |
AOR iShares Core 60/40 Balanced Allocation ETF | 3,071 | $213,439 | $210,993.05 | - | -$2,445.95 | -1.15% | +0.08% |
APA APA Corporation | 6,741 | $164,012.66 | $321,950.16 | - | $157,937.5 | 96.3% | +1.122% |
AVEM Avantis Emerging Markets Equity ETF | 32,753 | $2.28M | $2.94M | - | $658,639.28 | 28.93% | -0.863% |
AXP American Express Company | 2,109 | $572,259.28 | $671,357.97 | - | $99,098.69 | 17.32% | +1.421% |
BABA Alibaba Group Holding Limited SP ADR | 27,566 | $2.93M | $3.06M | - | $135,349.04 | 4.63% | -0.09% |
BAC Bank of America Corporation | 128,412 | $5.1M | $6.71M | - | $1.61M | 31.68% | +1.064% |
BF-B Brown-Forman Corporation | 259,241 | $7.02M | $7.53M | - | $507,024.46 | 7.22% | +1.645% |
BIIB Biogen Inc. | 1,702 | $244,952.03 | $397,689.32 | - | $152,737.29 | 62.35% | -0.718% |
BMRN Biomarin Pharmaceutical Inc. | 6,494 | $371,587 | $360,709.23 | - | -$10,877.77 | -2.93% | -0.901% |
BRK-A Berkshire Hathaway Inc. | 3 | $2.4M | $2.39M | - | -$7,325 | -0.31% | +0.825% |
BRK-B Berkshire Hathaway Inc. | 434,980 | $200.2M | $230.84M | - | $30.64M | 15.3% | +0.955% |
BTI British American Tobacco p.l.c. ADR | 127,523 | $4.67M | $7.58M | - | $2.91M | 62.24% | +2.483% |